Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Attention deficit disorder focus turns to side effects
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.